A new drug from Zogenix that treats a rare and severe type of epilepsy was approved by the Food and Drug Administration on Thursday — a decision that clears the way for the company to compete against a recently approved medicine derived from marijuana.
The Zogenix drug, called Fintepla, is a liquid solution administered to children born with Dravet syndrome, a severe type of epilepsy that causes frequent and prolonged seizures starting within the first year of life. Approximately 250 children in the U.S. are born with Dravet each year, and it affects about 20,000 people overall.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
"type" - Google News
June 26, 2020 at 07:05AM
https://ift.tt/2A8aOs4
Zogenix wins approval for new drug to treat rare type of childhood epilepsy - STAT
"type" - Google News
https://ift.tt/2WhN8Zg
https://ift.tt/2YrjQdq
Bagikan Berita Ini
0 Response to "Zogenix wins approval for new drug to treat rare type of childhood epilepsy - STAT"
Post a Comment